Tumor-associated MDSCs promote tumor progression by inducing tumor angiogenesis via the release of growth factors, cytokines, and metalloproteinases (e.g., VEGF, Bv8, MMP9) in response to tumor hypoxia and by STAT3 activation in MDSCs. Here, PROK2 is linked to neoplasm.